Amyndas Pharmaceuticals
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
  • Home
  • About
    • What We Do
    • Founder’s Bio
    • Management
  • Research & Development
    • Our Focus
    • Our Pipeline
    • Clinical Trials
    • Technology
    • Selected Publications
    • Notes on Targeted Conditions
  • News
  • Contact Us
  • LinkedIn
  • Twitter
on March 19, 2015
  • Research Focus

    Read about our priority clinical programs

  • Technology

    Learn more about our compound development

  • Publications

    Find links to relevant scientific papers and reviews

  • Latest News

    • Iatronet.gr: Φάρμακο με ελληνική “υπογραφή” για τη γεωγραφική ατροφία ωχράς κηλίδας

    • EUSTM (9th Congress): Novel Transformative Treatment for Periodontal Disease

    • Complement C3 inhibition in severe COVID-19 using compstatin AMY-101

    • Review: Compstatins: the dawn of clinical C3-targeted complement inhibition

     

    Latest Publications

    • Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis

    • Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy

    • The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

    • Complement as a target in COVID-19?

     
     

    Copyright © 2023 - Amyndas Pharmaceuticals. All Rights Reserved.